New depression patch put to the skin test

NCT ID NCT07452692

Not yet recruiting Knowledge-focused Sponsor: Corium Innovations, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares a new selegiline skin patch to an existing one (EMSAM®) to see how well the skin tolerates it. Researchers will apply both patches to 230 healthy adults and check for irritation or allergic reactions. The goal is to ensure the new patch is safe for the skin before further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selegiline transdermal patch
What this could lead to: If successful, this could confirm that the new selegiline patch is as skin-safe as the existing one, supporting its use for depression treatment.
What could go wrong: This is an early phase 1 trial focused on skin reactions, not on treating depression. It may not predict how well the patch works for depression or cause unexpected skin issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.